Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Rile LiAlan Pollack

Abstract

Proliferative activity defined by Ki-67 staining index (SI) has been correlated with progression and prognosis in a number of malignant tumors including prostate cancer. However, few studies have examined Ki-67 SI in pretreatment diagnostic material from patients treated with definitive radiotherapy. In a prior study, we found that a Ki-67 SI of >3.5% was associated with poorer patient outcome. The goals of this analysis were to validate the prognostic value of Ki-67 SI and this cut point. Of 456 assessable patients in Radiation Therapy Oncology Group Protocol 86-10, diagnostic material from 108 patients was available for Ki-67 analysis using MIB-1 antibody. Sixty patients were treated with external beam radiotherapy (EBRT) alone, and 48 patients were treated with short-term androgen deprivation + EBRT. Median follow-up was 9 years for those living. The relationship of Ki-67 with distant metastasis (DM), disease-specific survival (DSS), and overall survival (OS) was examined. The median Ki-67 SI was 7.1% (range, 0.2-45.5%). The 7.1% cut point was associated with DM and DSS; however, the 3.5% cut point was as strong a determinant and was the focus of this analysis. In Cox proportional hazards regression, Ki-67 SI was independent...Continue Reading

References

Jan 15, 1997·Journal of the National Cancer Institute·D J GrignonJ D Cox
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A PollackW U Shipley

❮ Previous
Next ❯

Citations

Mar 15, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Anthonius J BreeuwsmaIgle J de Jong
Mar 6, 2007·World Journal of Urology·Thorsten SchlommGuido Sauter
Apr 19, 2013·Cancer Metastasis Reviews·Jean-Emmanuel BibaultEric Deutsch
May 5, 2005·Current Urology Reports·Javier HernandezIan M Thompson
Jan 15, 2009·Journal of the National Cancer Institute·Vitaly MargulisShahrokh F Shariat
Nov 29, 2012·Journal of Cancer Research and Clinical Oncology·Naveen Kachroo, Vincent J Gnanapragasam
Nov 10, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jan Nyrop Jakobsen, Jens Benn Sørensen
Mar 5, 2016·Nuclear Medicine and Molecular Imaging·Soyeon ParkSungeun Kim
Jun 23, 2009·Cancer·Alessia Lopergolo, Nadia Zaffaroni
Jan 4, 2012·Histopathology·Glen Kristiansen
Sep 2, 2006·Critical Reviews in Oncology/hematology·H G van der Poel
Jul 4, 2006·International Journal of Radiation Oncology, Biology, Physics·Li-Yan KhorAlan Pollack
Nov 14, 2013·Prostate Cancer·Shane MeskoMitchell Kamrava
Apr 13, 2012·International Journal of Radiation Oncology, Biology, Physics·Patrick BouchaertGaelle Fromont
Apr 27, 2007·Genomics·Marina BibikovaJessica Wang-Rodriguez
Apr 27, 2016·International Journal of Radiation Oncology, Biology, Physics·Sarah MolinaGaëlle Fromont
Dec 1, 2006·Expert Review of Anticancer Therapy·Tanya B DorffJacek Pinski
Oct 8, 2011·Journal of Burn Care & Research : Official Publication of the American Burn Association·Hana FarhangkhoeeJoel S Fish
Dec 1, 2007·Advances in Anatomic Pathology·Milton W DattaMahul B Amin
Jan 19, 2013·British Journal of Cancer·G FisherUNKNOWN Transatlantic Prostate Group
May 16, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·James L MohlerDeborah A Freedman-Cass
Jun 20, 2020·Expert Review of Molecular Diagnostics·Stephan BrönimannShahrokh F Shariat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.